Our results support this classification: SH3BP5 expression strongly correlates with the activity of OXPHOS complexes (I, II, IV, V), functionally identifying SH3BP5-high tumors as OXPHOS-DLBCL, a subtype that directly influences treatment response. Here, SH3BP5 is linked to diffuse large B-cell lymphoma.